BioMarin receives positive CHMP opinion in Europe for Brineura™ (cerliponase alfa)
BioMarin announced the Committee for Medicinal Products for Human Use, the scientific committee of the EMA, has adopted a positive opinion for the company's MAA for Brineura™ (cerliponase alfa) to treat children with Neuronal Ceroid Lipofuscinosis Type 2 disease, a form of Batten disease. April 21, 2017